This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
These two volumes are evidently the first of a biennial series on the state of the art in preclinical and clinical psychopharmacology. Many such books are presently appearing. Why might we need these two volumes?
I came away from reading these books with much enthusiasm and only a few disappointments. It speaks for the strength of the psychiatric departments of Professors Hippius (who holds the former chair of Emile Kraepelin in Munich) and Winokur (of the University of Iowa Medical College, Iowa City) that they have provided half of the chapters in part 2. I liked in particular the chapters on neuroleptics, opiates, antidepressants, the monoamine oxidase inhibitors, lithium, and the tranquilizers.
Part 1 is most informative for the clinical researcher for comparison of different drugs and schools of thought about mechanism of action. I found the discussion of the new developments in antidepressants, dementia treatment, anxiety, and neuroleptic and
van Kammen DP. Psychopharmacology: A Biennial Critical Survey of the International Literature. JAMA. 1983;250(19):2704–2705. doi:10.1001/jama.1983.03340190096050
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: